Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medicine distributor would post earnings of $0.86 per share when it actually produced earnings of $0.90, delivering a surprise of 4.65%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Prestig ...

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our S ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the s ...

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highl ...

TARRYTOWN, N.Y., July 02, 2024 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2025 first quarter earnings release on Thursday, August 8, 2024 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To participate in the live Internet webcast of the conference call, it can be accessed from the Investor Relations page of www.prestigeconsumerhealthcare.com. To participate ...

Prestige Consumer Healthcare Inc. (PBH) delivered fourth-quarter fiscal 2024 earnings per share (EPS) of $1.02, a 4.7% decline from the year-ago period's figure. The metric also missed the Zacks Consensus Estimate by 10.5%. GAAP EPS for the quarter was 98 cents, a significant improvement from the year-ago loss of $4.78 per share. For the full year, adjusted EPS was $4.21, flat year over year. Revenues Total revenues in the fiscal fourth quarter declined 3.1% year over year (down 2.9% on an organic basis) to ...

Revenue Composition - In fiscal year 2024, North American OTC Healthcare accounted for 85.2% of total net revenues, while International OTC Healthcare represented 14.8%[26] - Major brands contributed approximately 83.3% of total revenues in 2024, with a number one market position for brands like BC and Goody's, Chloraseptic, and Dramamine[28] - In 2024, 58.6% of total revenues came from brands with a number one market position, a slight increase from 58.1% in 2023[32] - International sales represented 14.8% of total revenues in 2024, up from 10.9% in 2022, indicating a growing international presence[39] Product Development and Marketing - The company launched several new products in 2024, including Summer's Eve Ultimate Odor Protection line and Monistat's Maintain Boric Acid Suppositories, to drive growth[35] - The marketing strategy focuses on consumer-oriented initiatives, with significant investments in advertising and marketing to enhance brand growth[36] - The company’s sales are sensitive to new product introductions, with the potential for rapid market share capture by competitors[102] - Future product development and marketing efforts involve substantial expenditures that may not be recoverable if new products fail to gain market acceptance[121] Distribution and Sales Channels - Walmart accounted for approximately 19.7% of gross revenues in 2024, while Amazon accounted for about 10.9%[47] - The company has a diversified distribution strategy, with mass merchandisers contributing 34.6% of gross revenues in 2024[45] - The company manages product distribution in the continental United States through a third-party facility, which has been in operation since fiscal 2020[55] - The company has experienced changes in purchasing patterns, with a shift towards online purchases and reduced retail visits[79] Manufacturing and Supply Chain - As of March 31, 2024, the company had relationships with 122 third-party manufacturers, with long-term contracts with 26 manufacturers accounting for approximately 72.0% of gross revenues for 2024, up from 69.8% in 2023[50] - The company operates a manufacturing facility in Lynchburg, Virginia, which produces products representing approximately 11% of gross revenues[53] - The company relies on contract manufacturers for most of its production, minimizing capital expenditures and maximizing cash flow for reinvestment in marketing initiatives and debt repayment[49] - The company relies on third-party manufacturers for production, with a limited number of manufacturers causing potential risks to meeting customer demand[90] Economic and Regulatory Environment - The company is experiencing inflationary pressures, leading to frequent price increases in products due to fluctuations in input costs such as raw materials and labor[52] - Economic uncertainty due to global supply chain constraints, rising interest rates, and high inflation is expected to continue affecting demand for the company's products[79] - The company is subject to extensive regulation by U.S. federal agencies, including the FDA, which governs the formulation, manufacturing, and distribution of its products[60] - Compliance with various regulations has implications for capital expenditures and earnings, potentially delaying product introductions and requiring reformulation to meet new standards[74] Competition and Market Dynamics - The company faces significant competition in the OTC health and personal care market from both branded and private label products, impacting consumer purchasing behavior[56] - The introduction of store brand products at lower price points has impacted sales and could continue to do so, especially in the context of rising costs and economic conditions[105] - Volatility in economic conditions could reduce consumer spending, adversely impacting demand for the company's products[98] Financial Position and Debt - Total indebtedness as of March 31, 2024, was approximately $1.1 billion[140] - The aggregate amount of debt that would be immediately due and payable if both the senior credit facility and senior notes were accelerated is approximately $1.1 billion[148] - The company has not paid cash dividends in the past and does not expect to do so in the foreseeable future, focusing instead on operations, acquisitions, and debt repayment[179] - The company faces restrictions that limit its ability to engage in strategic acquisitions and may require a substantial portion of cash flow to service its debt[144] Human Resources and Diversity - The company employs approximately 570 global employees, with 53% female and 47% male, and 82% of the workforce based in the United States[83] - The company is committed to diversity and inclusion, actively promoting equal employment opportunities and employee development[82] Cybersecurity and Compliance - The company is subject to cybersecurity threats, which could result in data breaches and negatively impact operations[135] - The company has developed a comprehensive cybersecurity risk management program, which includes an incident response plan to address security breaches[160] - The cybersecurity risk management program is overseen by the Chief Financial Officer and includes regular training for all employees[170] Acquisitions and Goodwill - The company has a history of growth through acquisitions, including the acquisition of consumer health business assets from Akorn Operating Company LLC in 2022[38] - The company completed the acquisition of Akorn's consumer health business assets for a purchase price of $228.9 million in cash, enhancing its portfolio with brands like TheraTears[188] - Goodwill for North American OTC Healthcare was $498.936 million, while International OTC Healthcare goodwill was $28.797 million, totaling $527.733 million[202] - An impairment charge of $48.8 million was recorded on February 28, 2023, primarily due to increased discount rates from macroeconomic conditions[214]

Prestige Consumer Healthcare (PBH) reported $276.99 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 3.1%. EPS of $1.02 for the same period compares to $1.07 a year ago. View all Key Company Metrics for Prestige Consumer Healthcare here>>> Shares of Prestige Consumer Healthcare have returned +3.5% over the past month versus the Zacks S&P 500 composite's +2% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader mark ...

分组1 - Prestige Consumer Healthcare reported quarterly earnings of $1.02 per share, missing the Zacks Consensus Estimate of $1.14 per share, and down from $1.07 per share a year ago, representing an earnings surprise of -10.53% [1] - The company posted revenues of $276.99 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 3.46%, and down from $285.87 million year-over-year [2] - Prestige Consumer Healthcare shares have increased approximately 15.2% since the beginning of the year, outperforming the S&P 500's gain of 9.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $1.10 on revenues of $284.42 million, and for the current fiscal year, it is $4.61 on revenues of $1.16 billion [7] - The Zacks Industry Rank for Medical - Products is currently in the bottom 44% of over 250 Zacks industries, indicating that the industry outlook may impact stock performance [8]

[Executive Summary](index=1&type=section&id=Executive%20Summary) [CEO Commentary](index=1&type=section&id=CEO%20Commentary) FY24 delivered stable earnings and cash flow, despite Q4 supply chain pressures in eye care, with solid long-term fundamentals - **Fiscal Year 2024** delivered stable earnings and cash flow, supported by a leading brand portfolio and proven business strategy[3](index=3&type=chunk) - Fourth quarter performance was negatively affected by accelerated supply chain pressures, mainly in **eye care products**, limiting the ability to meet retailer order demand[3](index=3&type=chunk) - Long-term business fundamentals are solid, with **strong consumption** exceeding long-term expectations and **robust cash flow** providing options for shareholder value creation[3](index=3&type=chunk) [Key Highlights (Q4 & FY24)](index=1&type=section&id=Key%20Highlights%20(Q4%20%26%20FY24)) The company reported Q4 and FY24 revenues, reduced leverage to 2.8x, authorized a $300 million share repurchase, and provided an initial FY25 outlook Key Financial Metrics | Metric | Q4 FY24 | FY24 | | :------------------------------------------------ | :------ | :--------- | | Revenue | $277.0 Million | $1,125.4 Million | | Leverage Ratio (Year-End) | - | 2.8x | | Share Repurchase Program Authorization | - | $300 Million | | Initial FY25 Organic Revenue Growth Outlook | - | ~1% | | Initial FY25 EPS Outlook | - | $4.40 to $4.46 | - Solid consumption trends in Q4 were offset by near-term **supply chain constraints**[8](index=8&type=chunk) [Financial Performance - Fourth Fiscal Quarter Ended March 31, 2024](index=1&type=section&id=Financial%20Performance%20-%20Fourth%20Fiscal%20Quarter%20Ended%20March%2031,%202024) [Revenue Analysis (Q4)](index=1&type=section&id=Revenue%20Analysis%20(Q4)) Q4 FY24 revenues decreased by 2.9% to $277.0 million, primarily due to supply chain issues and private label exit, partially offset by International OTC growth Q4 Revenue Performance | Metric | Q4 FY24 (Millions) | Q4 FY23 (Millions) | Change (%) | | :-------------------------------- | :----------------- | :----------------- | :--------- | | Reported Revenues | $277.0 | $285.9 | -3.1% | | Revenues (Excl. FX Impact) | - | - | -2.9% | - Revenue decline attributed to inability to supply customer orders late in the quarter (certain brands), strategic exit of private label revenues, and lower Women's Health category sales[4](index=4&type=chunk) - Growth in the **International OTC segment** partially offset the overall revenue decline[4](index=4&type=chunk) [Net Income and EPS Analysis (Q4)](index=1&type=section&id=Net%20Income%20and%20EPS%20Analysis%20(Q4)) Q4 FY24 reported net income was $49.5 million, a significant improvement from prior year's loss due to no impairment charges; non-GAAP adjusted net income and EPS slightly decreased Q4 Net Income and EPS | Metric | Q4 FY24 | Q4 FY23 | Change | | :-------------------------- | :------ | :-------- | :----- | | Reported Net Income | $49.5M | $(240.6)M | Up | | Diluted EPS | $0.98 | $(4.83) | Up | | Non-GAAP Adjusted Net Income | $51.4M | $53.7M | Down | | Non-GAAP Adjusted Diluted EPS | $1.02 | $1.07 | Down | [Adjustments to Net Income (Q4)](index=1&type=section&id=Adjustments%20to%20Net%20Income%20(Q4)) Q4 FY24 and FY23 net income adjustments included tax rate adjustments; Q4 FY23 notably included non-cash tradename and goodwill impairments - Q4 FY24 and Q4 FY23 net income adjustments included **tax rate adjustments** for discrete items[6](index=6&type=chunk) - Q4 FY23 adjustments notably included **non-cash tradename impairments** (DenTek, Summer's Eve, TheraTears) and **goodwill impairments**, primarily due to higher discount rate assumptions[6](index=6&type=chunk) [Financial Performance - Fiscal Year Ended March 31, 2024](index=1&type=section&id=Financial%20Performance%20-%20Fiscal%20Year%20Ended%20March%2031,%202024) [Revenue Analysis (FY24)](index=2&type=section&id=Revenue%20Analysis%20(FY24)) FY24 revenues were $1,125.4 million, a slight decrease but 0.2% increase excluding FX, driven by International OTC and North American OTC growth, offset by category declines and private label exit FY24 Revenue Performance | Metric | FY24 (Millions) | FY23 (Millions) | Change (%) | | :-------------------------------- | :---------------- | :---------------- | :--------- | | Reported Revenues | $1,125.4 | $1,127.7 | -0.2% | | Revenues (Excl. FX Impact) | - | - | +0.2% | - Revenue performance was driven by strong **International OTC segment** and North American Eye & Ear Care, GI, and Dermatological category sales[9](index=9&type=chunk) - Offset by lower sales in Women's Health, Cough & Cold, and Analgesic categories, and the strategic exit of private label revenues[9](index=9&type=chunk) [Net Income and EPS Analysis (FY24)](index=2&type=section&id=Net%20Income%20and%20EPS%20Analysis%20(FY24)) FY24 reported net income was $209.3 million, a significant turnaround from prior year's loss; diluted EPS was $4.17, while non-GAAP adjusted net income and EPS remained stable FY24 Net Income and EPS | Metric | FY24 | FY23 | Change | | :-------------------------- | :------- | :-------- | :----- | | Reported Net Income | $209.3M | $(82.3)M | Up | | Diluted EPS | $4.17 | $(1.65) | Up | | Non-GAAP Adjusted Net Income | $211.3M | $212.0M | Stable | | Non-GAAP Adjusted Diluted EPS | $4.21 | $4.21 | Stable | [Adjustments to Net Income (FY24)](index=2&type=section&id=Adjustments%20to%20Net%20Income%20(FY24)) FY24 and FY23 net income adjustments included normalized tax rate adjustments; FY23 notably included non-cash tradename and goodwill impairments - FY24 and FY23 net income adjustments included **normalized tax rate adjustments** for discrete items[11](index=11&type=chunk) - FY23 adjustments included **non-cash tradename impairments** (DenTek, Summer's Eve, TheraTears) and **goodwill impairments**, along with associated tax adjustments[11](index=11&type=chunk) [Free Cash Flow and Balance Sheet](index=2&type=section&id=Free%20Cash%20Flow%20and%20Balance%20Sheet) [Cash Flow Performance](index=2&type=section&id=Cash%20Flow%20Performance) Net cash from operating activities and non-GAAP free cash flow both increased for Q4 FY24 and the full fiscal year 2024 Cash Flow Summary | Metric | Q4 FY24 (Millions) | Q4 FY23 (Millions) | FY24 (Millions) | FY23 (Millions) | | :-------------------------------- | :----------------- | :----------------- | :-------------- | :-------------- | | Net Cash Provided by Operating Activities | $66.9 | $59.0 | $248.9 | $229.7 | | Non-GAAP Free Cash Flow | $63.8 | $56.4 | $239.4 | $221.9 | [Debt and Leverage Ratio](index=2&type=section&id=Debt%20and%20Leverage%20Ratio) Net debt was ~$1.1 billion as of March 31, 2024, with a leverage ratio of 2.8x, below the 3x long-term goal, enhancing capital allocation flexibility Debt and Leverage | Metric | As of March 31, 2024 | | :-------------------- | :------------------- | | Net Debt Position | ~$1.1 Billion | | Covenant-Defined Leverage Ratio | 2.8x | - The leverage ratio of **2.8x** is below the stated long-term goal of **3x**, enabling maximized capital allocation optionality[15](index=15&type=chunk) [Share Repurchase Program Authorization](index=2&type=section&id=Share%20Repurchase%20Program%20Authorization) A new $300.0 million share repurchase program was authorized on May 6, 2024, aiming to maximize shareholder value and preserve financial flexibility - Board of Directors authorized a new share repurchase program of up to **$300.0 million** of common stock on May 6, 2024[14](index=14&type=chunk) - The program's goal is to maximize shareholder value while preserving financial flexibility for debt reduction or strategic acquisitions[15](index=15&type=chunk) [Segment Review](index=2&type=section&id=Segment%20Review) [North American OTC Healthcare](index=2&type=section&id=North%20American%20OTC%20Healthcare) North American OTC Healthcare revenues decreased in Q4 FY24 and FY24, primarily due to supply constraints, Women's Health decline, and private label exit, partially offset by growth in other categories North American OTC Healthcare Segment Revenues | Metric | Q4 FY24 (Millions) | Q4 FY23 (Millions) | FY24 (Millions) | FY23 (Millions) | | :-------------------- | :----------------- | :----------------- | :-------------- | :-------------- | | Segment Revenues | $231.1 | $242.3 | $958.3 | $973.8 | - Q4 revenue decline driven by